1Eriksson T, Bjorkinan S, Roth B, et al. Intravenous formtdatiom of the enantiomers of thalidomide: pharmacokinetic and initial pharmacodynamic characterization in man[J]. J Pharm Pharmacol,2000,52(7) :807.
2Komorowski J, Jerczynska H,Siejka A,et al .Effect of thalidomide affecting VEGF secretion, cell migration, adhesion and capillary tube formation of human endothdial EA. hy 926 cells[J]. Life Sci ,2006,78(22) : 2558.
3Kirfel G, Riqort A, Borm B,et al. Mechanisms of rear detachment and the formation of migration tracks [ J ]. Eur J Cell Biol, 2004,83 ( 11 - 12 ) : 717.
4Chodniewicz D, Klemke RL. Guiding cell migration through directed extension and stabilization of pseudopodia[ J]. Exp Cell Res, 2004, 301 (1):31.
5Tamilarasan KP, Kolluru GK, Rajaram M. Thalidomide attenuates nitric oxide mediated angiogenesis by blocking migration of endothelial cells [J]. BMC Cell Biol,2006,7:17.
6Tabu T, Tomimoto H, Taguchi Y. Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate [ J ]. Blood, 2005, 106 ( 1 ) : 125.
9Yasui K, Kohayashi N, Yamazaki T, et al.Thalidomide as an immunotherapeutic agent: the effects on neutrophil-mediated inflammation[J]. Curr Pharm Des,2005,11(3) :395.
10Teo SK. Properties of thalidomide and its analogues implications foranticancer therapy[J]. AAPS J,2005,7( 1 ) : E14.
2[4]BrandtJ, Haibel H, Cornely D, et a1. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infiiximab. ArthritiS Rheum, 2000, 43:1346- 52.
3[5]Van den Bosch F, Kruithof E, Baeten D, et al. Effects of a loading dose regimen of three infusions of chimeric monoclonsl antibody to tumour necrosis factor alpha (inflixmab)in spondyloarthropathy:an open pilot study [See comments]. Ann Rheum DiS, 2000,59:428-33.
4[6]Sampaio E, Sarno E,Galilly R, et al. Thalidomide selecdvely inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med,1991,173:699-703.
5[7]Sampaio E, Kaplan G, Miranda A,et al. The influence of thalidomide on the Clinical and immunologic manifestation of erythema nodosum leprostum. J Infect Dis, 1993,168:408-14.
6[8]Moreira A, Sampaio E, Zmuidzinnas A, et al. Thalidomide exerts its inhibitory action on tumor necroois factor alpHa by enhancing mRNA degradation. J Exp Med, 1993,177:1675-80.
7[9]Oliver S,Cheng T, Banquerigo M, et al. The effect of thalidomide and 2 analogs on collagen induced arthritis. J Rheumatol,1998,25:964-9.
8[10]Keesal N,Wasserman M, Bookman A,et a1. Thalidomide in the treatment of refractory rheumatoid arthritos. J Rheumatol, 1999,26:2344-7
9[11]Lenardo T,Calabrese L.The role of thalidomide in the treatment of rheumtic disesse. J Clin Rheumatol,2000,6:19-26.
10[12]Breban M, Gombert B, Amor B, et al. Efficacy of thalidomide in the treatment of refractory ankylosing spondylitis. Arthritis Rheum, 1999,42 : 580- 1.
